Get Smarter on Biotech in 5 Minutes a Day.
Focused insights — expertly curated, clearly delivered, ready for action.
Get the Daily Brief
What’s in Today’s Brief? (September 23rd Preview)
-
Phase 3 wins reshape IgA nephropathy competition with mRNA-targeted assets
Roche reported positive Phase 3 data for sefaxersen (formerly IONIS-FB-LRx) in primary IgA nephropathy, meeting endpoints in the Imagination study. The self-administered, once-monthly injection produced statistically significant and clinically meaningful improvements in proteinuria versus placebo at 37 weeks, measured by 24-hour urine protein-to-creatinine ratio. Analysts expect the results to support an accelerated FDA filing if Roche pursues U.S. approval. Sefaxersen would become the first mRNA-targeted therapy for IgAN, a kidney disease that saw its treatment landscape expand rapidly since the first IgAN approvals in the early 2020s. Roche has also positioned sefaxersen as part of a broader strategy in kidney disease—an area drawing heavy investment as companies look to differentiate on efficacy and treatment convenience. The Phase 3 readout increases pressure on peers already selling or advancing therapies in the crowded IgAN market.
-
Otsuka and Ionis score Phase 3 win in FUS-ALS, pushing for expedited regulator talks
Otsuka Pharmaceutical and Ionis Pharmaceuticals reported positive Phase 3 results from the Fusion study of ulefnersen in patients with FUS-associated amyotrophic lateral sclerosis. The antisense oligonucleotide met statistically significant improvements in function and survival, in a rare ALS subtype that has no approved targeted therapies. The companies said the data position ulefnersen for potential expedited regulatory discussions. The program is designed to target FUS biology in a way intended to modify disease progression rather than only manage symptoms. The Phase 3 success extends the momentum behind RNA-targeted precision medicine in neurodegeneration, as developers seek paths to accelerate access for genetically defined populations where unmet need remains high.
-
Amgen’s Sjögren’s therapy hits Phase 3 objectives after Horizon acquisition
Amgen announced preliminary Phase 3 results showing dazodalibep met key efficacy goals in Sjögren’s disease, a common autoimmune condition with no approved targeted therapy. The fusion protein, acquired as part of Amgen’s big Horizon Therapeutics deal, reduced disease severity in the trial data released. The readout strengthens Amgen’s late-stage pipeline built from Horizon assets and raises the prospect of a first-in-class Sjögren’s treatment. It also sets up increased competitive focus among companies targeting other immune pathways in dry-eye and systemic Sjögren’s. For investors, the Sjögren’s win signals continued integration of Horizon’s pipeline into Amgen’s development engine, with further milestones likely tied to trial completion details and regulatory timelines.
-
AI drugmakers accelerate with megafunding rounds and deeper clinical pipeline commitments
Enveda Biosciences raised $311 million in a Series E to fund advancement of an AI-driven pipeline with three oral candidates in human testing. The Nature-derived and microbe-derived chemistry approach is now moving beyond early validation, with Phase 2 and Phase 1 programs focused on atopic dermatitis, obesity and inflammatory bowel disease. The funding round was led by Catalio Capital Management, with participation from Surveyor Capital, T. Rowe Price, Lux Capital and a sovereign wealth fund. Enveda said it will use the capital to scale its platform while expanding development capabilities for later-stage programs. Separately, Basecamp Research secured an oversubscribed $140 million Series C supported by Anthropic via its Anthology Fund and other investors. The company plans to train next-generation EDEN models aimed at improving in vivo cell therapies across oncology and autoimmune disease, reflecting sustained investor demand for AI-native therapeutic design.
-
Radiopharma consolidation and isotope supply control moves to center stage
Telix agreed to acquire ITM Isotope Technologies Munich in a deal valued at up to $2.35 billion, with an $1.65 billion upfront component. Telix framed the transaction as a way to strengthen isotope supply and manufacturing capacity as radiopharmaceutical demand rises. The combined company would integrate development, production and distribution capabilities across multiple radioligand modalities, while ITM’s lead asset ITM-11 (¹⁷⁷Lu-edotreotide) is in Phase 3 for gastroenteropancreatic neuroendocrine tumors. Telix said the merger could reduce execution risk in a field where supply constraints can delay patient access. In parallel, Novartis also inked a potential $900 million licensing deal with Boomray Pharmaceuticals for a preclinical radioligand therapy asset, reinforcing how big pharma is building radiopharma pipelines amid increasing competition to Lutathera.
...and 5 more selected Biotech stories in today’s full edition — or archive.
Why BioBriefs?
- Expertly curated. We scan 200+ sources daily to deliver only what matters.
- Smart context. Each brief explains why it matters and who it impacts.
- Made for pros. Trusted by founders, scientists, investors, and strategists.
Who Reads BioBriefs?
- Biotech founders & execs
- R&D and Clinical leads
- Life sciences investors
- Regulators and BD pros
- Translational scientists and tech scouts
Stay sharp. Be first to what’s next.
About BioBriefs
We’re a team of biotech analysts, technical writers, and founders who know what it’s like to scan 40 tabs and still miss what matters. BioBriefs was built to solve that. We track the signals, condense the insights, and get them to you before your day starts.